Affordable Access

Access to the full text

Relapsed or primary refractory AML: moving past MEC and FLAG-ida

Authors
  • Koenig, Kristin
  • Mims, Alice
Type
Published Article
Journal
Current Opinion in Hematology
Publisher
Lippincott Williams And Wilkins
Publication Date
Jan 20, 2020
Volume
27
Issue
2
Pages
108–114
Identifiers
DOI: 10.1097/MOH.0000000000000561
PMID: 31904664
PMCID: PMC7015186
Source
PubMed Central
Keywords
License
Green

Abstract

Treatment of relapsed and refractory acute myeloid leukemia (AML) is still very challenging, with poor response rates and low chance for cure. This is especially true when treating patients who are elderly, have multiple comorbidities, or who are too unfit for traditional salvage chemotherapy regimens. Recent findings Recently, advances in the treatment of relapsed/refractory AML utilizing novel chemotherapy combinations, hypomethylating, and targeted therapies have shown promising results. Summary Several early-phase studies with novel targeted therapy combinations have demonstrated encouraging results warranting larger, comparative studies. This has expanded the access of treatment for patients with relapsed/refractory AML who cannot receive traditional salvage chemotherapy. These newer treatments have the potential to outperform traditional chemotherapy as well.

Report this publication

Statistics

Seen <100 times